Looking back at lung cancer Drug's Real-Life impact
NCT ID NCT06678555
Summary
This study looks back at medical records to understand how well the oral medication lorlatinib works for people with a specific type of advanced lung cancer (ROS1-positive NSCLC) that has stopped responding to other treatments. Researchers are analyzing data from 35 patients who already took the drug in real-world settings, not in a controlled trial. The goal is to see how long the drug helped control the cancer and extended life outside of a research environment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMA, NON-SMALL-CELL LUNG are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Pfizer Inc
Taipei, Taiwan
Conditions
Explore the condition pages connected to this study.